Key Highlights

• Double-digit growth was reported for the year to 30 June 2026.

• A trading update was released on 21 October 2026.

• Sigma supplies pharmacies and runs the Amcal and Discount Drug Stores banners.

• The group is now part of the Chemist Warehouse business.

How is Sigma Healthcare (ASX:SIG) performing now that it is part of the Chemist Warehouse business? The latest evidence is positive. The company reported double-digit growth for the year to 30 June 2026 and, on 21 October 2026, said Chemist Warehouse branded sales were still growing at a double-digit pace early in the new financial year. Integration, growth in new products and overseas expansion are the main things to watch.

What the company does

Sigma was historically a pharmaceutical wholesaler and distributor, supplying pharmacies and running the Amcal and Discount Drug Stores banners. Following its Merger with Chemist Warehouse, which took effect in February 2025, it now sits behind the largest pharmacy retail network in Australia. Its Revenue comes from wholesale and distribution to the Chemist Warehouse network, Franchise and related income, and its own banner brands, plus international operations.

The company says its global network is approaching 1,000 stores. Because a large share of Sigma's activity is tied to the Chemist Warehouse network, the health of that network is the key driver of earnings, and the company is exposed to anything that affects that network's customers, pricing or store roll-out.

The FY26 result

For the year to 30 June 2026, announced on 27 August 2026, Sigma reported normalised revenue of $10.8 billion, up 15.5% on pro forma FY25 of $9.4 billion. Normalised EBIT was $1,090.0 million, up 20.6%, with a Margin of 10.1%. Normalised net profit after tax was $732.3 million, up 22.3%, while statutory profit was $708.7 million.

Two points of interpretation matter here. First, normalised figures exclude merger, integration and purchase price accounting costs. Second, the prior-year comparison is pro forma, assuming the merger had applied from 1 July 2024, whereas statutory FY25 includes Sigma only from 12 February 2025. Statutory growth would therefore look different.

The board declared a final Dividend of 2.0 cents per share, fully franked, payable on 22 September 2026, making a full-year dividend of 4.0 cents and a Payout Ratio of 63.0%.

Segment and network performance

Australia generated revenue of $10,413.6 million, up 14.9%, and EBIT of $1,034.2 million, up 18.3%. The international segment produced revenue of $421.4 million, up 33.0%, and EBIT of $55.8 million, up 91.3%, from a much smaller base.

Australian Chemist Warehouse branded network sales were $10.2 billion, up 15.9%, with like-for-like growth of 13.4%. International store sales were $1.6 billion, up 23.3%. The network had 561 Australian stores, up 24, and 98 international stores, up 12.

Balance sheet and synergies

Net Debt fell to $663.2 million from $752.2 million, equal to 0.57 times normalised EBITDA compared with 0.85 times a year earlier. Management realised $32.6 million of cost synergies in FY26 and targets $100 million a year by FY29. That target is the company's own and remains subject to execution. Realised synergies of $32.6 million are about a third of the target, so most of the benefit is still to come.

FY27 Capital Expenditure is expected to be similar to FY26's $56.7 million.

Latest trading update

At the October 2026 AGM, Sigma reported Australian Chemist Warehouse branded store sales up 12.1% for 1 July to 16 October 2026, with like-for-like growth of 9.8%.

The company expects double-digit sales growth for the rest of the half, helped by Christmas trading. It reported that fragrances and supplements were softer, while healthcare, beauty and products supporting GLP-1 medicines performed encouragingly. It also anticipates introducing oral GLP-1 products in the second half of FY27.

Growth plans

Management expects double-digit revenue and Earnings growth in the first half of FY27, an expectation rather than a certainty. Planned openings for that half include 14 Chemist Warehouse stores and 42 Amcal and Discount Drug Stores in Australia, plus 19 international stores. The international programme includes the first entry into the United Kingdom. Sigma has said it holds just under 10% of Australian pharmacy licences and sees room to grow, although regulation governs how pharmacies may be owned and located.

Sector conditions and competitive position

Australian pharmacy is shaped by government pricing and Subsidy policy, ownership rules and consumer spending. Chemist Warehouse competes with other pharmacy groups, supermarkets and online retailers on price and range. Its scale gives purchasing power, and the merger has combined retail and wholesale capability under one roof.

GLP-1 medicines used for weight management are a growing category. Management has described the Demand as enduring, but they typically carry lower percentage margins.

Risks and what to watch

Key uncertainties include the following. Integration could take longer or cost more than expected. Growth may slow as comparisons lengthen. Changes to pharmaceutical pricing or licensing rules could affect margins. Product mix, including more lower-margin medicines, could dilute profitability. The UK entry carries execution risk in an unfamiliar market. Heavy reliance on one network concentrates exposure. Any slowdown in that network would therefore flow directly through to Sigma's results.

Upcoming items include Christmas trading, the first-half FY27 result, the progress of the synergy programme, and the UK store opening.

Bottom line

Sigma has delivered a encouraging first full year as the merged group, with net debt falling to 0.57 times normalised EBITDA and a clear programme of new stores. The next test is sustaining growth as comparisons toughen and as overseas expansion begins.